Simultaneously, we are establishing a clinical relationship with Baylor College of Medicine and/or Memorial Herman University of Texas Hospitals in Houston for in-hospital procedures with Congested Heart Disease (CDH) and Coronary Artery Disease (CAD).  

​

OUR MISSION:  This business is a culmination of years of scientific research and experimentation on the multiple benefits of PGE1 in patients with CHD, CAD, & PAD.  We aim to double life expectancy as compared to the present treatment.  

​

OBJECTIVES:  

• Increase pain-free walking (PFWD) by >300%

• We will establish ourselves as an "essential service" utilizing localized clinics having  

• PAD specialists available who will be familiar with the treatment protocols

• We will recruit 10 physician specialists as clinical investigators

• We will reduce treatment costs by 50% by maintaining an out-patient treatment protocol

• We will provide edge-to-edge services

• We will partner with a large hospital chain

• We are in consideration of partnering/licensing a large pharmaceutical firm

• We will secure a principal investigator as a well-known cardiologist/vascular specialist

• We will recruit the affluent, but no one will be turned away.

​

STRATEGICS:  We will grow by seeing up 10 outpatient treatment centers using physician clinics within the USA or PRC. These outpatient centers will grow to 100 in 3 years due to the proper care, coordination, and recovery of patients.  Patients will present to the center, be infused with the treatment drug, and return home to life normally.

 

We intend to measure life extension by years, not months.  We will provide maximum comfort, information on processes of care, as well self-care.   Fear and anxiety associated with illness can be as debilitating as the physical effects of the disease.  Our department will provide psychological, emotional, and spiritual support as an essential component to help accelerate healing for our patients.

 

ACTION PLAN:  Recruit a financial partner.  Enter into a binding contract agreement. File new patents. Get reviews and comments from 10 affluent entrepreneurs. Get commitment from CRO.  Run cost estimates on 10 treatment centers.  Distribute this business page plan to 100 investors in a 504 Reg D.  Raise $5-7 million using an annual coupon discount of 8% (minimum investment $25K) for whom will become investors in our initial public offering (IPO) in 2024.